Acute respiratory infections (ARIs) are a common cause of illness in children younger than 16 years and adults older than 65 ...

Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update $165.0 million icotrokinra (formerly JNJ-2113) milestone earned in Q4 2024, received in January ...

These new data further validate TP-317’s unique mechanism of action and its potential as an oral, first-in-class therapy for IBD,” said Gary Mathias, CEO of Thetis Pharmaceuticals. “The preclinical ...